 msnbc.com | Everolimus, exemestane improved outcomes in HT-resistant breast cancer HemOncToday Combining everolimus and exemestane improved PFS among postmenopausal women with advanced breast cancer resistant to hormonal therapy, according to data from a phase 3 trial. Results of the BOLERO-2 trial were presented at the 2011 European ... 'Strongest Ever Data' in Breast Cancer With Everolimus Afinitor (Everolimus) Prolongs Advanced Breast Cancer Patients' Progression ... Novartis drug Afinitor® helps women with advanced breast cancer live ... |
